Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Apellis Pharmaceuticals Inc APLS

Healthcare Biotechnology
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.


NDAQ:APLS - Post by User

Apellis Pharmaceuticals Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(291)
•••
Post by whytestockson Nov 05, 2024 8:00pm
51 Views
Post# 36297954

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial
NEWS: $APLS Apellis Pharmaceuticals Reports Third Quarter 2024 Financial ResultsGenerated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product sales Grew SYFOVRE&#xAE; (pegcetacoplan injection) demand by 7% quarter-over-quarter, with U.S. net product revenue of $152.0 million Increase in demand offset by higher gross-to-net adjustm...APLS - Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities